Compare · CNC vs NTRA
CNC vs NTRA
Side-by-side comparison of Centene Corporation (CNC) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $38.64B, about 1.2x CNC ($31.55B).
- Over the past year, CNC is up 119.5% and NTRA is up 88.3% - CNC leads by 31.1 points.
- NTRA has been more active in the news (25 items in the past 4 weeks vs 12 for CNC).
- Both have 25 recent analyst ratings on file.
- Company
- Centene Corporation
- Natera Inc.
- Price
- $63.91-4.04%
- $269.96-2.69%
- Market cap
- $31.55B
- $38.64B
- 1M return
- +0.78%
- +24.38%
- 1Y return
- +119.45%
- +88.33%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 12
- 25
- Recent ratings
- 25
- 25
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest CNC
- CENTENE CORPORATION TO HOST 2026 SECOND QUARTER FINANCIAL RESULTS EARNINGS CALL
- CENTENE SUBSIDIARY MERIDIAN HEALTH PLAN OF ILLINOIS AWARDED ILLINOIS MEDICAID CONTRACT
- Director Tyler Lauren M was granted 61 shares (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 465 shares, increasing direct ownership by 2% to 25,213 units (SEC Form 4)
- Director Tanji Kenneth was granted 581 shares, increasing direct ownership by 5% to 12,490 units (SEC Form 4)
- Director Eppinger Frederick H was granted 833 shares, increasing direct ownership by 0.23% to 369,538 units (SEC Form 4)
- Director Coughlin Christopher J was granted 562 shares, increasing direct ownership by 3% to 18,711 units (SEC Form 4)
- Health Net Providing Special Assistance to Members and Providers Affected by Palos Warehouse Fire in Los Angeles
- RBC Capital Mkts initiated coverage on Centene with a new price target
- CENTENE APPOINTS LAUREN M. TYLER TO BOARD OF DIRECTORS
Latest NTRA
- Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
- CO-FOUNDER Sheena Jonathan sold $836,898 worth of shares (3,150 units at $265.68) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 246,202 units (SEC Form 4)
- Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $280,000 worth of shares (1,000 units at $280.00) as part of a pre-agreed trading plan (SEC Form 4)
- SEC. AND CHIEF LEGAL OFFICER Rabinowitz Daniel sold $4,574,431 worth of shares (16,800 units at $272.29) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 172,294 units (SEC Form 4)
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $818,710 worth of shares (3,000 units at $272.90) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 134,643 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update
- Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
- Director Lynch Thomas J. Jr. was granted 1,905 shares (SEC Form 4)
- Director Marcus Gail Boxer was granted 1,669 shares, increasing direct ownership by 27% to 7,852 units (SEC Form 4)